文献速递淋巴瘤

真实世界环境中套细胞淋巴瘤新型治疗的影响:英国血液系统恶性肿瘤研究网络(HMRN)报告

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
PubMed 文献 · Br J Haematol · 2018-03-13

该研究基于英国HMRN人群中2004至2015年诊断的335例套细胞淋巴瘤患者,分析一线及复发/难治疾病的治疗与生存变化。一线利妥昔单抗免疫治疗从32%升至86%,中位生存从2004-2011年治疗的2.0年升至2012-2015年的3.5年;复发/难治疾病结局从8个月改善至16.8个月,与苯达莫司汀和伊布替尼等药物引入同步。

要点

  • 一线利妥昔单抗免疫治疗从32%升至86%,中位生存从2.0年升至3.5年。
  • 复发/难治疾病结局从8个月改善至16.8个月,与苯达莫司汀和伊布替尼引入同步。
  • 70岁以上复发/难治患者1年总生存几乎翻倍,各年龄组均见改善。

核心结论

  • 真实世界中套细胞淋巴瘤的治疗和生存发生显著变化,临床试验的生存改善已转化为真实世界结局。
  • 作者强调监测真实世界治疗变化影响的重要性。

研究设计与样本

  • 基于英国HMRN已建立的人群队列,纳入2004至2015年诊断的335例套细胞淋巴瘤患者,分析一线及复发/难治疾病管理及人口学、诊断和预后因素。

主要发现

  • 一线利妥昔单抗免疫治疗从32%增至86%(11年期间)。
  • 中位生存从2004-2011年首次治疗的2.0年增至2012-2015年治疗的3.5年。
  • 复发/难治疾病结局从2004-2011年的8个月改善至2012-2015年的16.8个月,与苯达莫司汀和伊布替尼等药物引入同步。
  • 70岁以上复发/难治患者1年总生存几乎翻倍,各年龄组均见改善。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment landscape for mantle cell lymphoma (MCL) has changed dramatically in recent years, with findings from clinical trials reporting improvements in survival. Data on the general patient population are, however, sparse; and it is unclear whether the effects observed in clinical trials have translated into the real-world setting. To investigate this, we examined first-line and relapsed/refractory (RR) disease management in 335 MCL patients diagnosed between 2004 and 2015 in an established population-based patient cohort, along with data on demographic, diagnostic and prognostic factors. Marked treatment and survival changes were observed; first-line rituximab immunotherapy, for example, increased from 32% to 86% over the 11-year period, and median survival increased from 2·0 years among those first treated in 2004-2011 to 3·5 years among those treated in 2012-2015. Outcomes for RR disease also improved, from 8 months in 2004-2011 to 16·8 months in 2012-2015, coinciding with the introduction of agents, such as bendamustine and ibrutinib. Encouragingly, improvements were seen across all ages; 1-year overall survival among patients over 70 years treated for RR disease almost doubled. Our analyses underscore the importance of monitoring the impact of treatment changes in the real-world setting.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Smith A, Roman E, Appleton S, et al. Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN). Br J Haematol. 2018. PMID: 29532919. doi:10.1111/bjh.15170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。